JPS6337625B2 - - Google Patents

Info

Publication number
JPS6337625B2
JPS6337625B2 JP56084789A JP8478981A JPS6337625B2 JP S6337625 B2 JPS6337625 B2 JP S6337625B2 JP 56084789 A JP56084789 A JP 56084789A JP 8478981 A JP8478981 A JP 8478981A JP S6337625 B2 JPS6337625 B2 JP S6337625B2
Authority
JP
Japan
Prior art keywords
medium
present
organic acid
dme
dulbecco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP56084789A
Other languages
Japanese (ja)
Other versions
JPS57202288A (en
Inventor
Masahiro Mizuguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissui Pharmacetuical Co Ltd
Original Assignee
Nissui Pharmacetuical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissui Pharmacetuical Co Ltd filed Critical Nissui Pharmacetuical Co Ltd
Priority to JP56084789A priority Critical patent/JPS57202288A/en
Publication of JPS57202288A publication Critical patent/JPS57202288A/en
Publication of JPS6337625B2 publication Critical patent/JPS6337625B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Description

【発明の詳細な説明】 本発明は高圧滅菌可能な新規なダルベツコ変法
イーグル培地(以下、DME培地と称する)に関
する。 DME培地はアール・ダルベツコ(R.
Dulbecco)らによつて開発された培地であり、
公知のイーグルMEM中のアミノ酸濃度を約2倍
及びビタミン濃度を約4倍にすることにより培養
細胞の増殖に必要な栄養源を豊富にし、これに更
にグリシン、セリン、ピルビン酸及び鉄イオンを
添加した改良型のイーグルMEMであり、種々の
細胞の初代培養や単細胞培養を行う目的で広く使
用されている。特にDME培地は、細胞にウイル
スを感染させたのち血清を含まない培地に変えて
も細胞を長く維持できる培地として広く使用され
ている。 このDME培地は当初は液体培地であつたが、
その後製法の改良がなされ、現在は長期間保存可
能な粉末培地として提供されている。 しかしながら、当該粉末培地は、その使用に先
立つて溶解され滅菌処理されなければならない。
培地の滅菌法として、現在最も効果的かつ操作の
簡単な方法は高圧滅菌法である。しかし、従来の
DME培地は、これを高圧滅菌処理に付すと、細
胞増殖に対する支持力が著しく低下するので、細
菌過器による滅菌を余儀無くされていた。しか
しながら、細菌過器による滅菌法は、細菌効果
が不充分であると共に多くの手数と時間を要する
欠点があり、従来から、高圧滅菌可能なDME培
地の開発が所望されていた。 そこで、本発明者は斯る問題点を解決せんと鋭
意研究を行つた結果、当該培地の処方中の熱に対
して不安定なものを除去乃至は他のもので代替
し、かつ有機酸緩衝剤を含有せしめることによ
り、高圧滅菌処理を行つても細胞増殖に対する支
持力の低下のみられないDME培地が得られるこ
とを見出し、本発明を完成した。 すなわち、本発明はDME培地の処方中からL
―グルタミン及びL―シスチンを除去し、代りに
L―システイン並びに有機酸とその塩との組合せ
からなる有機酸緩衝剤を含有せしせた高圧滅菌型
DME培地を提供するものである。 本発明で使用される有機酸緩衝剤としては、PH
が4.25になるもの、例えば酢酸と酢酸ナトリウ
ム、コハク酸とコハク酸ナトリウム等が好まし
い。 本発明の高圧滅菌型DME培地の代表的処方
(以下、本発明培地粉末と称する)は次のとおり
である。 塩化ナトリウム 6400.0(mg) 塩化カリウム 400.0 塩化カルシウム 200.0 硫酸マグネシウム 97.7 リン酸二水素ナトリウム(無水) 108.0 硝酸第二鉄(九水塩) 0.1 ブドウ糖 1000.0 ピルビン酸ナトリウム 110.0 コハク酸 106.0 コハク酸ナトリウム(六水塩) 27.0 L―アルギニン塩酸塩 84.0 L―システイン塩酸塩(一水塩) 70.3 グリシン 30.0 L―ヒスチジン塩酸塩(一水塩) 42.0 L―イソロイシン 104.8 L―ロイシン 104.8 L―リジン塩酸塩 146.2 L―メチオニン 30.0 L―フエニルアラニン 66.0 L―セリン 42.0 L―スレオニン 95.2 L―トリプトフアン 16.0 L―チロシン二ナトリウム 89.5 L―バリン 93.6 重酒石酸コリン 7.2 葉酸 4.0 ニコチン酸アミド 4.0 パントテン酸カルシウム 4.0 ピリドキサール塩酸塩 4.0 リボフラビン 0.4 チアミン塩酸塩 4.0 i―イノシトール 7.2 フエノールレツド 5.0 全量 9503.0 本発明高圧滅菌型DME培地は上記成分を常法
に従つて混和することにより製造される。尚
DME培地には一般に細胞の増殖を図るために10
%前後の血清を添加して使用するが、血清の添加
量が少ない場合、L―シスチンの代りにL―シス
テインを含有させた本発明培地の高圧滅菌に対す
る有利性は特に顕著である。 次に実施例を挙げて説明する。 実施例 1 DME培地粉末(市販品)10.0gを1の蒸
留水に溶解し、炭酸水素ナトリウム1.2gを加
えて完全に溶解させた。これをポアサイズ0.2μ
のフイルターで過滅菌して、DME培地(以
下、従来培地と称する)を得た。 本発明培地粉末9.5gを1の蒸留水に溶解
し、121℃で15分間高圧滅菌し、これに冷後、
溶解、過滅菌したL―グルタミン0.584g及
び炭酸水素ナトリウム1.2gを加えて培地(本
発明培地と称する)を得た。 本発明培地粉末の処方中のL―システイン塩
酸塩・一水塩(70.3mg)の代りにL―シスチン
二塩酸塩(62.6mg)を加えたものを、と同様
に操作して培地(比較培地と称する)を得た。 上で得た3つの培地に新生子牛の血清を濃度が
2%になるように加え、次の条件下でヒト子宮ガ
ン細胞由来の細胞株Hela―S3の培養を行い、そ
の増殖を調べた。 φ6cmプラスチツクシヤーレ(培地量5ml)植
込細胞数5×104セル/Dish37℃、5%炭酸ガス。 その結果は第1図に示すとおりである。 実施例 2 実施例1の〜と同様にして調整した各培地
にヒト子宮ガン細胞由来の細胞株Hela―S3の培
養を行い、そのコロニー形成率を調べた。ただし
血清濃度は5%及び2%の場合について調べた。
各測定とも5枚のシヤーレにより調べた結果を次
表に示す。 【表】
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel Dulbecco's modified Eagle medium (hereinafter referred to as DME medium) that can be sterilized under high pressure. DME medium was prepared by Earl Dulbetsko (R.
This is a medium developed by Dulbecco et al.
By doubling the amino acid concentration and quadrupling the vitamin concentration of the known Eagle MEM, we enriched the nutrients necessary for the growth of cultured cells, and further added glycine, serine, pyruvate, and iron ions. This is an improved type of Eagle MEM, which is widely used for primary culture and single cell culture of various cells. In particular, DME medium is widely used as a medium that can maintain cells for a long time even if cells are infected with a virus and then changed to a serum-free medium. This DME medium was initially a liquid medium, but
The manufacturing method has since been improved, and it is now available as a powdered medium that can be stored for a long period of time. However, the powdered medium must be dissolved and sterilized prior to its use.
Currently, the most effective and easy-to-operate method for sterilizing culture media is high-pressure sterilization. However, traditional
When a DME medium is subjected to high-pressure sterilization, its supporting capacity for cell growth is significantly reduced, so sterilization using a bacterial strainer has been unavoidable. However, the sterilization method using a bacterial strainer has the disadvantage that it has insufficient bactericidal effects and requires a lot of labor and time, and there has been a desire for the development of a DME medium that can be sterilized under high pressure. Therefore, the inventor of the present invention conducted intensive research to solve these problems, and as a result, removed or replaced the heat-labile substances in the formulation of the medium, and added an organic acid buffer. The present invention was completed based on the discovery that a DME medium that does not lose its supporting capacity for cell growth even after high-pressure sterilization can be obtained by containing the agent. That is, the present invention provides L from the formulation of DME medium.
- High-pressure sterilization type that removes glutamine and L-cysteine and instead contains L-cysteine and an organic acid buffer consisting of a combination of an organic acid and its salt.
It provides a DME medium. The organic acid buffer used in the present invention includes PH
is preferably 4.25, such as acetic acid and sodium acetate, succinic acid and sodium succinate, etc. A typical formulation of the autoclaved DME medium of the present invention (hereinafter referred to as the medium powder of the present invention) is as follows. Sodium chloride 6400.0 (mg) Potassium chloride 400.0 Calcium chloride 200.0 Magnesium sulfate 97.7 Sodium dihydrogen phosphate (anhydrous) 108.0 Ferric nitrate (nonahydrate) 0.1 Glucose 1000.0 Sodium pyruvate 110.0 Succinic acid 106.0 Sodium succinate (hexahydrate) ) 27.0 L-arginine hydrochloride 84.0 L-cysteine hydrochloride (monohydrate) 70.3 Glycine 30.0 L-histidine hydrochloride (monohydrate) 42.0 L-isoleucine 104.8 L-leucine 104.8 L-lysine hydrochloride 146.2 L-methionine 30.0 L-phenylalanine 66.0 L-serine 42.0 L-threonine 95.2 L-tryptophan 16.0 L-tyrosine disodium 89.5 L-valine 93.6 Choline bitartrate 7.2 Folic acid 4.0 Nicotinamide 4.0 Calcium pantothenate 4.0 Pyridoxal hydrochloride 4.0 Riboflavin 0 .4 Thiamin hydrochloride Salt 4.0 i-inositol 7.2 Phenol red 5.0 Total amount 9503.0 The autoclaved DME medium of the present invention is produced by mixing the above components in a conventional manner. still
DME medium generally contains 10
When the amount of serum added is small, the advantage of the medium of the present invention containing L-cysteine instead of L-cysteine in autoclaving is particularly remarkable. Next, an example will be given and explained. Example 1 10.0 g of DME medium powder (commercially available) was dissolved in 1 distilled water, and 1.2 g of sodium bicarbonate was added to completely dissolve it. This has a pore size of 0.2μ.
The DME medium (hereinafter referred to as conventional medium) was obtained by over-sterilizing with a filter. Dissolve 9.5 g of the present invention medium powder in 1 distilled water, autoclave at 121°C for 15 minutes, and after cooling,
A medium (referred to as the medium of the present invention) was obtained by adding 0.584 g of dissolved and oversterilized L-glutamine and 1.2 g of sodium bicarbonate. A medium (comparison medium ) was obtained. Newborn calf serum was added to the three media obtained above to a concentration of 2%, and the cell line Hela-S3 derived from human uterine cancer cells was cultured under the following conditions, and its proliferation was examined. . φ6cm plastic jar (medium volume: 5ml), number of implanted cells: 5 x 104 cells/dish, 37°C, 5% carbon dioxide gas. The results are shown in FIG. Example 2 Cell line Hela-S3 derived from human uterine cancer cells was cultured in each culture medium prepared in the same manner as in Example 1 to examine the colony formation rate. However, the serum concentration was investigated at 5% and 2%.
The following table shows the results of each measurement using five sheets of shear glass. 【table】

【図面の簡単な説明】[Brief explanation of the drawing]

第1図は高圧滅菌した本発明培地に血清2%を
添加したものにおけるHeLa―S3株の増殖状態を
示す。
FIG. 1 shows the growth state of HeLa-S3 strain in an autoclaved medium of the present invention to which 2% serum was added.

Claims (1)

【特許請求の範囲】 1 ダルベツコ変法イーグル培地の処方中からL
―グルタミン及びL―シスチンを除去し、代りに
L―システイン並びに有機酸とその塩との組合せ
からなる有機酸緩衝剤を含有せしめたことを特徴
とする高圧滅菌型ダルベツコ変法イーグル培地。 2 有機酸緩衝剤がコハク酸とコハク酸ナトリウ
ムとの組合せである特許請求の範囲第1項記載の
高圧滅菌型ダルベツコ変法イーグル培地。
[Claims] 1 L from the formulation of Dulbecco's modified Eagle's medium
- An autoclaved Dulbecco's modified Eagle medium characterized in that glutamine and L-cystine have been removed and, instead, an organic acid buffer consisting of L-cysteine and a combination of an organic acid and its salt is contained. 2. The autoclaved Dulbecco's modified Eagle medium according to claim 1, wherein the organic acid buffer is a combination of succinic acid and sodium succinate.
JP56084789A 1981-06-02 1981-06-02 Dulbecco modified eagle medium of high-pressure sterilization type Granted JPS57202288A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP56084789A JPS57202288A (en) 1981-06-02 1981-06-02 Dulbecco modified eagle medium of high-pressure sterilization type

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56084789A JPS57202288A (en) 1981-06-02 1981-06-02 Dulbecco modified eagle medium of high-pressure sterilization type

Publications (2)

Publication Number Publication Date
JPS57202288A JPS57202288A (en) 1982-12-11
JPS6337625B2 true JPS6337625B2 (en) 1988-07-26

Family

ID=13840460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56084789A Granted JPS57202288A (en) 1981-06-02 1981-06-02 Dulbecco modified eagle medium of high-pressure sterilization type

Country Status (1)

Country Link
JP (1) JPS57202288A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01303225A (en) * 1988-05-28 1989-12-07 Daifuku Co Ltd Vessel supplying device on article classifying equipment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01303225A (en) * 1988-05-28 1989-12-07 Daifuku Co Ltd Vessel supplying device on article classifying equipment

Also Published As

Publication number Publication date
JPS57202288A (en) 1982-12-11

Similar Documents

Publication Publication Date Title
Neuman et al. Dual requirement of Walker carcinosarcoma 256 in vitro for asparagine and glutamine
Roberts et al. Further studies of glutamic acid decarboxylase in brain
Rueckert et al. Studies on unbalanced growth in tissue culture: I. Induction and consequences of thymidine deficiency
CN108251353B (en) Human embryo in-vitro culture solution and culture system
CN104911143B (en) A kind of no albumen, serum free medium without hydrolysate and preparation method thereof
CN109337862B (en) Sperm washing solution and preparation method and application thereof
CN108251355A (en) Single step embryo medium
Swim et al. The role of carbon dioxide as an essential nutrient for six permanent strains of fibroblasts
CN105454220A (en) Placenta preservation method, placenta preservation solution and preparation method thereof
Moser Modern approaches to the study of mammalian cells in culture
US3936355A (en) Microorganism growth media and the stabilization thereof
JPS6337625B2 (en)
CN115433705B (en) Chemically defined medium for culturing BHK21 cells, additive and application thereof
Kay The inhibition of bacteriophage multiplication by proflavine and its reversal by certain polyamines
CN110669724A (en) Saccharum embryo culture solution and preparation method thereof
BE1022290B1 (en) FERMENTATION PROCESS
Hanss et al. Studies of culture media for the growth of human tumor cells
JPS60114192A (en) Culture method and medium of ant poison gland cell
GB1192340A (en) Improvements in or relating to Tissue Culture media
CN114540274A (en) Serum-free medium, preparation method thereof and method for culturing 2BS (2 BS) cells by using serum-free medium
JPH06189781A (en) Stabilization of bioactive protein in culture solution
SU1654338A1 (en) Nutrient medium for restoration after cryoconservation of hybridous mammalian cells, mus musculus l - producers antiinfluenza monoclonal antibodies
CN117210401B (en) Preparation and culture medium for promoting mesenchymal stem cell adherent growth and preparation method thereof
CN116790483A (en) CHO cell serum-free medium and application thereof
Garnett The effect of arginine deprivation on the cytopathogenic effect and replication of human cytomegalovirus